Logo image of LLY.DE

ELI LILLY & CO (LLY.DE) Stock Fundamental Analysis

FRA:LLY - Deutsche Boerse Ag - US5324571083 - Common Stock - Currency: EUR

662.4  -10 (-1.49%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to LLY. LLY was compared to 51 industry peers in the Pharmaceuticals industry. LLY scores excellent on profitability, but there are some minor concerns on its financial health. LLY is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

LLY had positive earnings in the past year.
LLY had a positive operating cash flow in the past year.
Each year in the past 5 years LLY has been profitable.
In the past 5 years LLY always reported a positive cash flow from operatings.
LLY.DE Yearly Net Income VS EBIT VS OCF VS FCFLLY.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

1.2 Ratios

Looking at the Return On Assets, with a value of 12.42%, LLY belongs to the top of the industry, outperforming 82.35% of the companies in the same industry.
LLY's Return On Equity of 70.45% is amongst the best of the industry. LLY outperforms 98.04% of its industry peers.
LLY's Return On Invested Capital of 27.17% is amongst the best of the industry. LLY outperforms 96.08% of its industry peers.
LLY had an Average Return On Invested Capital over the past 3 years of 21.71%. This is significantly above the industry average of 15.19%.
The 3 year average ROIC (21.71%) for LLY is below the current ROIC(27.17%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.42%
ROE 70.45%
ROIC 27.17%
ROA(3y)11.42%
ROA(5y)11.8%
ROE(3y)60.64%
ROE(5y)70.77%
ROIC(3y)21.71%
ROIC(5y)19.96%
LLY.DE Yearly ROA, ROE, ROICLLY.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

LLY's Profit Margin of 22.66% is amongst the best of the industry. LLY outperforms 82.35% of its industry peers.
LLY's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 40.25%, LLY belongs to the best of the industry, outperforming 96.08% of the companies in the same industry.
LLY's Operating Margin has improved in the last couple of years.
LLY has a better Gross Margin (81.70%) than 82.35% of its industry peers.
In the last couple of years the Gross Margin of LLY has remained more or less at the same level.
Industry RankSector Rank
OM 40.25%
PM (TTM) 22.66%
GM 81.7%
OM growth 3Y12.38%
OM growth 5Y7.84%
PM growth 3Y6.05%
PM growth 5Y-8.8%
GM growth 3Y3.11%
GM growth 5Y0.62%
LLY.DE Yearly Profit, Operating, Gross MarginsLLY.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), LLY is creating value.
Compared to 1 year ago, LLY has about the same amount of shares outstanding.
The number of shares outstanding for LLY has been reduced compared to 5 years ago.
LLY has a worse debt/assets ratio than last year.
LLY.DE Yearly Shares OutstandingLLY.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
LLY.DE Yearly Total Debt VS Total AssetsLLY.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.2 Solvency

An Altman-Z score of 7.48 indicates that LLY is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.48, LLY belongs to the top of the industry, outperforming 96.08% of the companies in the same industry.
LLY has a Debt/Equity ratio of 2.19. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.19, LLY is not doing good in the industry: 74.51% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.19
Debt/FCF N/A
Altman-Z 7.48
ROIC/WACC2.81
WACC9.66%
LLY.DE Yearly LT Debt VS Equity VS FCFLLY.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10B 20B

2.3 Liquidity

LLY has a Current Ratio of 1.37. This is a normal value and indicates that LLY is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of LLY (1.37) is comparable to the rest of the industry.
LLY has a Quick Ratio of 1.06. This is a normal value and indicates that LLY is financially healthy and should not expect problems in meeting its short term obligations.
LLY has a better Quick ratio (1.06) than 62.75% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.06
LLY.DE Yearly Current Assets VS Current LiabilitesLLY.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 89.01% over the past year.
Measured over the past years, LLY shows a quite strong growth in Earnings Per Share. The EPS has been growing by 16.57% on average per year.
LLY shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.38%.
The Revenue has been growing by 15.08% on average over the past years. This is quite good.
EPS 1Y (TTM)89.01%
EPS 3Y16.75%
EPS 5Y16.57%
EPS Q2Q%29.46%
Revenue 1Y (TTM)36.38%
Revenue growth 3Y16.73%
Revenue growth 5Y15.08%
Sales Q2Q%45.17%

3.2 Future

Based on estimates for the next years, LLY will show a very strong growth in Earnings Per Share. The EPS will grow by 30.37% on average per year.
LLY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.76% yearly.
EPS Next Y68%
EPS Next 2Y51.7%
EPS Next 3Y42.22%
EPS Next 5Y30.37%
Revenue Next Year31.67%
Revenue Next 2Y25.5%
Revenue Next 3Y22.67%
Revenue Next 5Y17.76%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
LLY.DE Yearly Revenue VS EstimatesLLY.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B 100B
LLY.DE Yearly EPS VS EstimatesLLY.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20 40 60

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 53.90, LLY can be considered very expensive at the moment.
Based on the Price/Earnings ratio, LLY is valued a bit more expensive than the industry average as 64.71% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Earnings ratio of 26.68, LLY is valued quite expensively.
The Price/Forward Earnings ratio is 24.78, which indicates a rather expensive current valuation of LLY.
The rest of the industry has a similar Price/Forward Earnings ratio as LLY.
LLY's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.50.
Industry RankSector Rank
PE 53.9
Fwd PE 24.78
LLY.DE Price Earnings VS Forward Price EarningsLLY.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, LLY is valued a bit more expensive than the industry average as 64.71% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 34.74
LLY.DE Per share dataLLY.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of LLY may justify a higher PE ratio.
LLY's earnings are expected to grow with 42.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.79
PEG (5Y)3.25
EPS Next 2Y51.7%
EPS Next 3Y42.22%

More info and screens

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.82%, LLY is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.09, LLY has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.36, LLY's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.82%

5.2 History

The dividend of LLY is nicely growing with an annual growth rate of 15.60%!
Dividend Growth(5Y)15.6%
Div Incr Years6
Div Non Decr Years6
LLY.DE Yearly Dividends per shareLLY.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3 4 5

5.3 Sustainability

43.74% of the earnings are spent on dividend by LLY. This is a bit on the high side, but may be sustainable.
LLY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP43.74%
EPS Next 2Y51.7%
EPS Next 3Y42.22%
LLY.DE Yearly Income VS Free CF VS DividendLLY.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B 6B 8B 10B
LLY.DE Dividend Payout.LLY.DE Dividend Payout, showing the Payout Ratio.LLY.DE Dividend Payout.PayoutRetained Earnings

More info and screens

ELI LILLY & CO

FRA:LLY (5/19/2025, 10:38:59 AM)

662.4

-10 (-1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners83.27%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap627.95B
Analysts81.21
Price Target891.32 (34.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.82%
Yearly Dividend4.41
Dividend Growth(5Y)15.6%
DP43.74%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.92%
Min EPS beat(2)6.45%
Max EPS beat(2)9.38%
EPS beat(4)3
Avg EPS beat(4)11.23%
Min EPS beat(4)-20.34%
Max EPS beat(4)49.43%
EPS beat(8)7
Avg EPS beat(8)29.89%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)11
Avg EPS beat(16)14.81%
Revenue beat(2)0
Avg Revenue beat(2)-0.87%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.5%
Revenue beat(4)1
Avg Revenue beat(4)1.15%
Min Revenue beat(4)-6.46%
Max Revenue beat(4)12.82%
Revenue beat(8)4
Avg Revenue beat(8)2.39%
Revenue beat(12)5
Avg Revenue beat(12)0.98%
Revenue beat(16)9
Avg Revenue beat(16)1.3%
PT rev (1m)-6.1%
PT rev (3m)-5.63%
EPS NQ rev (1m)0.18%
EPS NQ rev (3m)0.71%
EPS NY rev (1m)-5.77%
EPS NY rev (3m)-6.13%
Revenue NQ rev (1m)0.4%
Revenue NQ rev (3m)0.6%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)0.29%
Valuation
Industry RankSector Rank
PE 53.9
Fwd PE 24.78
P/S 14.34
P/FCF N/A
P/OCF 75.44
P/B 44.59
P/tB 176.52
EV/EBITDA 34.74
EPS(TTM)12.29
EY1.86%
EPS(NY)26.73
Fwd EY4.03%
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)8.78
OCFY1.33%
SpS46.18
BVpS14.86
TBVpS3.75
PEG (NY)0.79
PEG (5Y)3.25
Profitability
Industry RankSector Rank
ROA 12.42%
ROE 70.45%
ROCE 33.25%
ROIC 27.17%
ROICexc 28.73%
ROICexgc 36.37%
OM 40.25%
PM (TTM) 22.66%
GM 81.7%
FCFM N/A
ROA(3y)11.42%
ROA(5y)11.8%
ROE(3y)60.64%
ROE(5y)70.77%
ROIC(3y)21.71%
ROIC(5y)19.96%
ROICexc(3y)23.23%
ROICexc(5y)21.74%
ROICexgc(3y)32.89%
ROICexgc(5y)32.31%
ROCE(3y)29.19%
ROCE(5y)26%
ROICexcg growth 3Y1.59%
ROICexcg growth 5Y4.02%
ROICexc growth 3Y9.55%
ROICexc growth 5Y8.81%
OM growth 3Y12.38%
OM growth 5Y7.84%
PM growth 3Y6.05%
PM growth 5Y-8.8%
GM growth 3Y3.11%
GM growth 5Y0.62%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 2.19
Debt/FCF N/A
Debt/EBITDA 1.6
Cap/Depr 578.92%
Cap/Sales 21.61%
Interest Coverage 250
Cash Conversion 43.23%
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.06
Altman-Z 7.48
F-Score6
WACC9.66%
ROIC/WACC2.81
Cap/Depr(3y)374.28%
Cap/Depr(5y)279.43%
Cap/Sales(3y)16.34%
Cap/Sales(5y)12.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.01%
EPS 3Y16.75%
EPS 5Y16.57%
EPS Q2Q%29.46%
EPS Next Y68%
EPS Next 2Y51.7%
EPS Next 3Y42.22%
EPS Next 5Y30.37%
Revenue 1Y (TTM)36.38%
Revenue growth 3Y16.73%
Revenue growth 5Y15.08%
Sales Q2Q%45.17%
Revenue Next Year31.67%
Revenue Next 2Y25.5%
Revenue Next 3Y22.67%
Revenue Next 5Y17.76%
EBIT growth 1Y73.83%
EBIT growth 3Y31.18%
EBIT growth 5Y24.1%
EBIT Next Year96.28%
EBIT Next 3Y44.1%
EBIT Next 5Y29.16%
FCF growth 1Y-133.54%
FCF growth 3Y-57.48%
FCF growth 5Y-34.68%
OCF growth 1Y36.68%
OCF growth 3Y6.69%
OCF growth 5Y12.76%